Weekly Report: what happened at OPK last week (0520-0524)?
Weekly Report · 3d ago
Ondas Holdings And 2 Other Stocks Under $2 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern about the company's prospects. Qurate Retail, Inc. President/CEO David Rawlinson bought a total of 100,000 shares at an average price of $. Ondas Holdings Inc. And OPKO Health are recent notable insider transactions for penny stocks.
Benzinga · 6d ago
Monday 5/20 Insider Buying Report: OPK, OUST
NASDAQ · 05/20 17:38
$3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed above the $40,000 mark on Friday. When insiders purchase or sell shares, it indicates their confidence or concern about the company's prospects. Recent notable insider transactions for penny stocks include Tecogen Inc. And Standard BioTools Inc. OPKO Health, Inc. Also had a recent notable insider transaction.
Benzinga · 05/20 12:36
Weekly Report: what happened at OPK last week (0513-0517)?
Weekly Report · 05/20 09:13
Noteworthy Friday Option Activity: OPK, JBHT, CVNA
NASDAQ · 05/17 19:18
Weekly Report: what happened at OPK last week (0506-0510)?
Weekly Report · 05/13 09:13
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
NASDAQ · 05/09 13:18
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Upstart Holdings, Inc. Shares fell 10.3% to $21.96 on Wednesday. The company reported first-quarter revenue of $128 million and issued second-quarter guidance below estimates. Reborn Coffee, Inc (NASDAQ:REBN) shares jumped 132.9% after the company announced expansion into China.
Benzinga · 05/08 17:38
Analysts’ Top Healthcare Picks: Opko Health (OPK), Pharming Group (PHAR)
TipRanks · 05/08 13:40
OPKO Health Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones · 05/08 13:37
HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target
Benzinga · 05/08 13:14
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Repare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday's pre-market session. The company's, Q1 earnings came out yesterday. CEL-SCI stock increased by 13.1%. Myriad Genetics and Envoy Medical also moved upwards.
Benzinga · 05/08 12:06
Piper Sandler Sticks to Its Buy Rating for Opko Health (OPK)
TipRanks · 05/08 11:10
Opko Health Poised for Growth: Buy Rating Affirmed Amid Topline Expansion and Strategic Transactions
TipRanks · 05/08 10:28
Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Shares of Flywire Corporation fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter results. Flywire posted a quarterly loss of 5 cents per share, compared to market expectations for a loss of 2 cents. The company's shares dipped 14.1% to $17.65 in pre- market trading. U.S. Stock futures were slightly higher this morning.
Benzinga · 05/08 10:05
Opko Health (OPK) Q1 2024 Earnings Call Transcript
Opko Health's (OPK) first-quarter 2024 financial results conference call will be held May 7, 2024. The company's CEO, Phillip Frost, will discuss the company's financial results for the first quarter of 2024. Dr. Elias Zerhouni will provide an overview of BioReference Health. Adam Logal, OPKO's CFO, will also discuss the financial results.
The Motley Fool · 05/08 01:15
OPK Stock Earnings: OPKO Health Misses EPS, Misses Revenue for Q1 2024
OPKO Health reported earnings per share of -12 cents for the first quarter of 2024. The company reported revenue of $173.70 million. This was below the analyst estimate of $182.99 million. OPKO Health also reported results for the fourth quarter of 2015.
Investorplace · 05/08 00:57
OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 05/08 00:30
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/07 21:30
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.